Other research analysts also recently issued research reports about the stock. Stifel Nicolaus raised their price target on shares of Sinclair Pharma PLC from GBX 49 ($0.64) to GBX 63 ($0.82) and gave the company a buy rating in a report on Wednesday, September 14th. Peel Hunt raised their price target on shares of Sinclair Pharma PLC from GBX 66 ($0.86) to GBX 68 ($0.89) and gave the company a buy rating in a report on Thursday, September 1st. Jefferies Group cut their price target on shares of Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a buy rating on the stock in a report on Wednesday, June 15th. Finally, Royal Bank Of Canada restated an outperform rating on shares of Sinclair Pharma PLC in a report on Thursday, September 15th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Sinclair Pharma PLC presently has a consensus rating of Buy and a consensus target price of GBX 57 ($0.74).
Shares of Sinclair Pharma PLC (LON:SPH) opened at 27.375 on Wednesday. The firm’s market cap is GBX 136.05 million. Sinclair Pharma PLC has a 1-year low of GBX 26.25 and a 1-year high of GBX 61.33. The company’s 50-day moving average is GBX 29.43 and its 200 day moving average is GBX 32.38.
About Sinclair Pharma PLC
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.